{
  "ptid_time": "027_S_2336_2016-06-30",
  "img_path": "/data/qiuhui/data/adni/images/027_S_2336/2016-06-30/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 37,716 mm³, 34.4% above the reference mean. With a Z-score of 0.79 (78.4th percentile), this represents normal volume ; hippocampal volume measures 6,470 mm³, 9.1% below the reference mean. With a Z-score of -0.83 (20.3th percentile), this represents normal volume ; whole brain volume measures 829,586 mm³, 14.9% below the reference mean. With a Z-score of -1.87 (3.0th percentile), this represents moderate atrophy; entorhinal cortex volume measures 3,071 mm³, 16.4% below the reference mean. With a Z-score of -1.01 (15.7th percentile), this represents mild atrophy; fusiform gyrus volume measures 13,466 mm³, 20.8% below the reference mean. With a Z-score of -1.90 (2.9th percentile), this represents moderate atrophy; middle temporal gyrus volume measures 13,952 mm³, 27.2% below the reference mean. With a Z-score of -2.36 (0.9th percentile), this represents significant atrophy. ",
  "text_data": "Age is 77.9 years. Gender is Female. Education: 12 years. MMSE: 28.0. MoCA: 20.0. Logical Memory: 4.0. APOEε4 alleles: 1.0. ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows moderate to significant atrophy in key Alzheimer's-related regions (whole brain, entorhinal cortex, fusiform gyrus, middle temporal gyrus), while hippocampal volume is only mildly reduced. The MoCA score of 20/30 suggests cognitive impairment, but the MMSE (28/30) is near-normal, indicating possible early-stage decline. The presence of one APOE4 allele increases Alzheimer's risk.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely amnestic subtype, given temporal lobe atrophy and borderline hippocampal volume).  \n\n**Confidence:** **Medium** (imaging strongly suggests neurodegeneration, but the discrepancy between MMSE and MoCA, along with the absence of severe hippocampal atrophy, makes early dementia less certain).  \n\n*Note: Follow-up clinical correlation (e.g., neuropsychological testing, CSF biomarkers, or amyloid PET) would strengthen confidence.*",
  "timestamp": "2025-07-26T03:56:26.957663"
}